CTLA4 and melanoma: Enhancer of zeste homolog 2 blockade led to reduced PD-L1 mRNA levels and a decrease in PD-L1+ Pax3+ in melanoma cells, which was maintained during concomitant IL-2cx or anti-CTLA-4 immunotherapy [74].